Viking Therapeutics (VKTX) has been attracting investor interest for quite a while, all thanks to the rapid progress of its pipeline candidates targeting obesity and non-alcoholic steatohepatitis (NASH) indications. This year, management reported encouraging results on its obesity and NASH drug programs. These results position the company's pipeline candidates strongly against currently available therapies targeting these diseases. So far this year, the stock has surged 197.3% against the industry's 6.3% de ...

It's a tough act to follow. Few biotech companies have made more noise than Viking Therapeutics (VKTX 4.41%) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks to excellent clinical progress. The biotech's shares are up by 154% since early January. Why Viking Therapeutics has been on fire Among this herd of drugmakers -- outside of Eli Lilly and Novo Nordisk -- Viking Therapeutics ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 EarninConference Call April 24, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Joon Lee - Truist Kambiz Yazdi - Jefferies Annabel Samimy - Stifel Jay Olson - Oppenheimer Andrew Hsieh - William Blair Nick Econom - Raymond James Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Co Justin Zelin - BTIG Operator ...

Exhibit 99.1 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 24, 2024 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corpo ...

Start Time: 08:30 January 1, 0000 9:18 AM ET Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2023 Earnings Conference Call February 07, 2024, 16:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group. Andy Hsieh - William Blair. Thomas Smith - Leerink Partners. Yale Jen - Laidlaw & Company. Joe Pantginis - HC Wainwright. Jack Padov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) ( State or other jurisdiction of incorporation ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Conference Call October 25, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Joon Lee - Truist Securities Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Joseph Pantginis - HC Wainwright Andy Hsieh - William Blair Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Steven Seedhouse - Raymond James Jay Olson - Oppenheimer Joon Lee - Truist Securities Andy Hsieh - William Blair Yale Jen - Laidlaw & Co Thomas Smith - Leerink Partners Justin Zelin - BTIG Dylan Dupuis - Roth MKM Operator Welcome to the Viking Therapeutics Second Quart ...